TheraRadar
← Back
Data updated: Jun 28, 2026

NAARI PTE

Generics

NAARI PTE is a generic drug manufacturer focused on Dermatology.

2015
Since
9
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

NAARI PTE's Key Drugs

NAARI PTE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

NAARI PTE's Recent FDA Approvals

New NDA/BLA approvals for NAARI PTE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

NAARI PTE's Therapeutic Areas

NAARI PTE's approved drugs and pipeline span 1 therapeutic area, led by Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 100%
1 drugs

NAARI PTE's Top Competitors

NAARI PTE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

NAARI PTE Pipeline Snapshot

Active clinical trials for NAARI PTE across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Dermatology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling